Idera Pharmaceuticals is a clinical-stage patient-focused biopharmaceutical company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while our third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA.
|Bank Name||Idera Pharmaceuticals, Inc.|
|Industry||Biotechnology: Biological Products|
|CEO||Mr. Vincent J. Milano|